文献速递临床试验与 GCP

老年大型手术中术中氯胺酮预防术后谵妄或疼痛:一项国际多中心双盲随机临床试验

Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.
PubMed 文献 · Lancet · 2017-05-30

PODCAST研究为国际多中心双盲随机试验,纳入672例60岁以上全麻大型心脏及非心脏手术患者,随机接受安慰剂、氯胺酮0.5 mg/kg或1.0 mg/kg。合并氯胺酮组与安慰剂组谵妄发生率无差异(19.45% vs 19.82%,绝对差0.36%,95%CI -6.07至7.38,p=0.92),随氯胺酮剂量增加术后幻觉(p=0.01)和噩梦(p=0.03)增多。作者认为单次亚麻醉剂量氯胺酮未减少老年大型手术后谵妄,且可能因诱导负性体验而造成伤害。

要点

  • 合并氯胺酮组与安慰剂组术后谵妄发生率无差异(19.45% vs 19.82%,p=0.92)。
  • 随氯胺酮剂量增加,术后幻觉(p=0.01)和噩梦(p=0.03)较安慰剂增多。
  • 不良事件各单项(p值均>0.40)及合并(36.9% vs 39.6% vs 40.8%,p=0.69)组间无显著差异。

核心结论

  • 单次亚麻醉剂量氯胺酮未减少老年大型手术后谵妄,且可能因诱导负性体验而造成伤害。

研究设计与样本

  • PODCAST研究为国际多中心双盲随机临床试验,纳入60岁以上全麻大型心脏及非心脏手术成人。
  • 采用计算机生成随机序列按15例区组将患者随机分为安慰剂(生理盐水)、低剂量氯胺酮(0.5 mg/kg)或高剂量氯胺酮(1.0 mg/kg)组,于麻醉诱导后、手术切皮前给药。
  • 共评估1360例患者,672例被随机分配:安慰剂组222例、0.5 mg/kg氯胺酮组227例、1.0 mg/kg氯胺酮组223例。
  • 术后前3天每日两次采用Confusion Assessment Method评估谵妄,按意向治疗分析并评估不良事件。

主要发现

  • 合并氯胺酮组与安慰剂组谵妄发生率无差异(19.45% vs 19.82%,绝对差0.36%,95%CI -6.07至7.38,p=0.92)。
  • 与安慰剂相比,随氯胺酮剂量增加术后幻觉(p=0.01)和噩梦(p=0.03)增多。
  • 不良事件(心血管、肾脏、感染、胃肠道及出血)单项比较p值均>0.40,合并发生率安慰剂组36.9%、0.5 mg/kg氯胺酮组39.6%、1.0 mg/kg氯胺酮组40.8%(p=0.69),组间无显著差异。

临床怎么用

  • 作者认为单次亚麻醉剂量氯胺酮未减少老年大型手术后谵妄,且可能因诱导负性体验而造成伤害。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium is a common and serious postoperative complication. Subanaesthetic ketamine is often administered intraoperatively for postoperative analgesia, and some evidence suggests that ketamine prevents delirium. The primary purpose of this trial was to assess the effectiveness of ketamine for prevention of postoperative delirium in older adults. METHODS: The Prevention of Delirium and Complications Associated with Surgical Treatments [PODCAST] study is a multicentre, international randomised trial that enrolled adults older than 60 years undergoing major cardiac and non-cardiac surgery under general anaesthesia. Using a computer-generated randomisation sequence we randomly assigned patients to one of three groups in blocks of 15 to receive placebo (normal saline), low-dose ketamine (0·5 mg/kg), or high dose ketamine (1·0 mg/kg) after induction of anaesthesia, before surgical incision. Participants, clinicians, and investigators were blinded to group assignment. Delirium was assessed twice daily in the first 3 postoperative days using the Confusion Assessment Method. We did analyses by intention-to-treat and assessed adverse events. This trial is registered with clinicaltrials.gov, number NCT01690988. FINDINGS: Between Feb 6, 2014, and June 26, 2016, 1360 patients were assessed, and 672 were randomly assigned, with 222 in the placebo group, 227 in the 0·5 mg/kg ketamine group, and 223 in the 1·0 mg/kg ketamine group. There was no difference in delirium incidence between patients in the combined ketamine groups and the placebo group (19·45% vs 19·82%, respectively; absolute difference 0·36%, 95% CI -6·07 to 7·38, p=0·92). There were more postoperative hallucinations (p=0·01) and nightmares (p=0·03) with increasing ketamine doses compared with placebo. Adverse events (cardiovascular, renal, infectious, gastrointestinal, and bleeding), whether viewed individually (p value for each >0·40) or collectively (36·9% in placebo, 39·6% in 0·5 mg/kg ketamine, and 40·8% in 1·0 mg/kg ketamine groups, p=0·69), did not differ significantly across groups. INTERPRETATION: A single subanaesthetic dose of ketamine did not decrease delirium in older adults after major surgery, and might cause harm by inducing negative experiences. FUNDING: National Institutes of Health and Cancer Center Support.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet. 2017. PMID: 28576285. doi:10.1016/S0140-6736(17)31467-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。